White Papers
Ketoprofen
Date: 06.2023
FDA says NSAIDS increase risk of heart attack
Date: 09.27.2021
New ACP Guidelines for Treatment of Acute Non Low Back Pain-Topical NSAIDs First-Line Therapy
Date: 08.31.2020
Date: 02.11.2019
Gabapentin
Plasma concentration of oral gabapentin dose not increase proportionally with increase dosing
Date: 04.12.21
Transdermal Gabapentin: The Route Less Traveled
Date: 10.13.2024
A multimodal approach to optimize pharmacotherapy and improve safety outcomes in chronic neuropathy
Why Gabapentin may become a Schedule V controlled substance
Date: 01.30.2020
Topical Gabapentin use on CRPS
Date: 10.29.2019
Date: 10.09.2017
Naltrexone
Focus: Addiction drug shows promise lifting long COVID brain fog, fatigue
Date: 10.18.2022
CHICAGO, Oct 18 (Reuters) - Lauren Nichols, a 34-year-old logistics expert for the U.S. Department of Transportation in Boston, has been suffering from impaired thinking and focus, fatigue, seizures, headache and pain since her COVID-19 infection in the spring of 2020. Last June, her doctor suggested low doses of naltrexone, a generic drug typically used to treat alcohol and opioid addiction. After more than two years of living in "a thick, foggy cloud," she said, "I can actually think clearly." (Read more...)
Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study
Date: 10.24.2022
Up to 37.7% of patients experience symptoms beyond 12 weeks after infection with SARS-CoV-2. To date care for people with long covid has centred around multidisciplinary rehabilitation, self care and self pacing. LDN is safe in patients with PCS and may improve well-being and reduce symptomatology in this cohort. Randomised control trials are needed to further explore this. (Read more...)
Low-Dose Naltrexone Could Treat Long COVID Symptoms
Date: 6.7.2023
Naltrexone is a drug approved by the Food and Drug Administration (FDA) to treat alcohol use disorder and opioid addiction. Low-dose naltrexone (LDN), usually at a fraction of the regular dose, has been used to treat fibromyalgia and multiple sclerosis. (Read more...)
Lidocaine
Date: 1.20.2025
Transdermal anesthesia is a cornerstone of pain management, offering localized analgesia with minimal systemic effects. Lidocaine, a widely utilized local anesthetic, achieves pain relief primarily through sodium channel blockade, with emerging evidence highlighting additional mechanisms such as modulation
of inflammatory mediators and nociceptive signaling. This review of the literature investigates Lidocaine 7.5% Cream as a potentially superior option compared to 4-5% lidocaine formulations and EMLA cream (lidocaine 2.5% and prilocaine 2.5%). With its higher concentration, Lidocaine 7.5% Cream may provide deeper, longer-lasting anesthesia while mitigating risks such as prilocaine-induced methemoglobinemia and delayed onset associated with EMLA Cream. Through the integration of published pharmacokinetic,
pharmacodynamic, and clinical trial data we evaluate the suitability of lidocaine 7.5% (w/w) in the management of localized musculoskeletal and neuropathic pain. Our findings suggest lidocaine 7.5% cream offers improved efficacy and tolerability vs FDA approved alternatives; however, additional PK/PD studies and clinical trials must be conducted to further optimize dose and formula. (Read more...)
Newsletter